The breakneck speed of scientific research is resulting in a pile of unaddressed ethical questions.
For example: scientists have moved beyond invitro fertilization to assemble stem cells into embryolike structures. While this may be innocent at the moment, it’s a short walk tissues and organs and eventually take on the features of a mature human being.
All of a sudden ethicists are talking about “synthetic human entities with embryolike features”. It’s a slippery slope.
Read Carl Zimmer’s piece over at the Times for more.
Lyme disease: a bacterial disease vectored by ticks that can cause long-term health issues.
It turns out that a vaccine was developed when lyme disease was first discovered to be a serious problem on Cape Cod. AWESOME! FIGHT THOSE TERRIBLE DISEASES!
But anti-vaccine advocates protested that the vaccine caused arthritis (a symptom which was never seen in clinical trials, and there is no evidence linking arthritis to the vaccine) and in the media backlash it was taken off the market.
So although it exists, and your dog can get vaccinated and live a lyme disease free life, we the people cannot. Read all about it here.
The World Health Organization announced its first list of antibiotic-resistant “priority pathogens” on Monday, detailing 12 families of bacteria that agency experts say pose the greatest threat to human health and kill millions of people every year.
The list isn’t meant to scare people, but to call attention to microbes for which research into antibiotics is needed.
Read about it at the Washington Post.
In a deeply divided country, some people are dreading going home for the holidays. The anticipation of political conversation, about who voted for who, and about the racist, misogynist bigot who is planning to soon lead the United States.
So instead of talking through some of these issues (although I encourage civil discord!), the New York Times has given us a list of science and health stories from 2016 that you can discuss instead!
You could talk about how science views fat and what we know about weight loss! Or instead of talking about fleeing the country, perhaps consider a move to Mars instead! Or you can talk about dogs, and what science knows about their relationships!
Or you can talk about climate change, funding rates, the importance of teaching evolution and minorities in STEM! Not recommended by the NYTimes but always recommended by NiB.
Also, consider subscribing to the New York Times.
An 8 million dollar study came out in the Lancet ~5 years ago claiming that if you have Chronic Fatigue Syndrome, otherwise known as myalgic encephalomyelitis, the best treatment is exercise and psychotherapy.
However, after years of demanding they release their data (which they did under a court order), it has now been revealed that the study was just plain bad science.
Read about the controversy, the study, and the retraction (hopefully) over at STAT.
Sure, finding new and interesting species and describing them is exciting.
But finding new bacteria that cause a well understood disease? Equally if not more exciting (my little parasitic loving heart is all aflutter!).
While it has long been thought that lyme disease is caused by one bacterium (Borrelia burgdorferi), researchers at Mayo Clinic found something floating around in blood samples of people suspected of having Lyme disease that is totally different.
It has been named Borrelia mayonii, and it is remarkably similar to it’s lyme disease causing brethren. But it also has some important differences.
Read all about it over at NPR
Usually when an industry gets a booming industry it is largely due to profitability, which garners interest from investors.
But in biotech there is a section of the industry that is gaining investors and various firms chasing a similar goal. However, how that is happening is a mystery. The companies are burning through millions, hasn’t started clinical work on a drug candidate and it will be years, “if ever” before it has something commercializable.
What industry am I referring to? CRISPR-Cas9 technology. We’ve talked on the blog before about the possibilities CRISPR has to offer human health, but over at The Economist here’s a post about whether or not it can be all we dream it to be.